Pharma 101 - Pharmaceutical Fraud
FDA Launches Draft Guidelines On Financial Ties With Drug Companies
If an outside expert has more than $50,000 in ties to drug and medical device companies regulated by the Food and Drug Administration he will be barred from advising the FDA under the new draft guidelines. The money calculations include corporate grants, contracts, consulting fees and/or company stock. Although it was not clear how many advisors would be disqualified, Randall Lutter, the Food and Drug Administration’s acring commissioner for policy, said it was a “significant number.”
No Tags
To read more click here. To learn more about drug company inducements as a violation of the False Claims Act, click here.
| Posted By Marcella Auerbach | |
| Category Legal | Posted March 23rd, 2007 |
| Bookmark | |
Leave a Reply
Regulatory Documents (PDF)
- OIG Compliance Program Guidance for Pharmaceutical Manufacturers
- Medicaid Rebate Applicability of Physician Administered Drugs
Nolan Law Firm Articles
- Pages
- Categories
- Clinical Trials (2)
- Legal (36)
- Medicare (4)
- Off-Label (2)
- Pharmaceutical (2)
- Feeds
- Archives
Nolan & Auerbach, P.A. is a qui tam law firm whose practice is uniquely limited to healthcare fraud cases under the qui tam provisions of the False Claims Act. We know healthcare fraud because that's what we do! Toll free: 800-FRAUD 04
"The hiring of a lawyer is an important decision that should not be based
solely on advertisements. Before you decide, ask us to send you free written
information about our qualifications and experience."
Licensed in Florida
Located in Fort Lauderdale, Florida
Available for National Cases